References
- Beasley R, Ellwood P, Asher I. International patterns of the prevalence of pediatric asthma the ISAAC program. Pediatr Clin North Am 2003;50:539–553
- Strachan D, Sibbald B, Weiland S, et al. Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC). Pediatr Allergy Immunol 1997;8:161–176
- Malone DC, Lawson KA, Smith DH, et al. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol 1997;99:22–27
- Kim SY, Yoon SJ, Jo MW, et al. Economic burden of allergic rhinitis in Korea. Am J Rhinol Allergy 2010;24:e110–e113
- Oh HA, Seo JY, Jeong HJ, Kim HM. Ginsenoside Rg1 inhibits the TSLP production in llergic rhinitis mice. Immunopharmacol Immunotoxicol 2013. [Epub ahead of print]. doi:10.3109/08923973.2013.837061
- Park EK, Choo MK, Han MJ, Kim DH. Ginsenoside Rh1 possesses antiallergic and anti-inflammatory activities. Int Arch Allergy Immunol 2004;133:113–120
- Zheng H, Jeong Y, Song J, Ji GE. Oral administration of ginsenoside Rh1 inhibits the development of atopic dermatitis-like skin lesions induced by oxazolone in hairless mice. Int Immunopharmacol 2011;11:511–518
- Sun J, Song X, Hu S. Ginsenoside Rg1 and aluminium hydroxide synergistically promote immune responses to ovalbumin in Balb/c mice. Clin Vaccine Immunol 2008;15:303–307